SCHEDULE: Macquarie Divests Entire Travere Therapeutics Stake

Macquarie Group Limited and its affiliates have filed an amended Schedule 13G, reporting zero beneficial ownership in Travere Therapeutics Inc.

Summary

• Macquarie Group Limited, Macquarie Management Holdings Inc, and Macquarie Investment Management Business Trust jointly filed an Amendment No. 1 to Schedule 13G.
• The filing indicates that the reporting persons now beneficially own 0.00 shares of Travere Therapeutics Inc. Common Shares.
• This represents 0.00% of the class of securities.
• The event date requiring this filing was 12/31/2025.
• The filing certifies that the securities were acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development for Travere Therapeutics, as a significant institutional holder has fully divested its position, potentially signaling a lack of confidence.

Negatives

• Macquarie Group Limited and its affiliates have reduced their beneficial ownership in Travere Therapeutics Inc. to 0.00%.
• This indicates a complete divestment of their previously held stake, which could be perceived negatively by the market.

Industry Context

StockSavvy.ai notes that institutional investor divestments, especially from significant holders like Macquarie, can sometimes signal a shift in investment strategy or a re-evaluation of the issuer's prospects within the biotechnology or pharmaceutical sector. While this filing doesn't provide reasons, such exits are closely watched by the market.

Stakeholder Impact

• Shareholders: May react negatively to the news of a major institutional investor divesting its entire stake, potentially leading to downward pressure on the stock price.

Key Dates

Recommendation

The complete divestment by Macquarie Group Limited and its affiliates, reducing their beneficial ownership to 0.00%, suggests a significant institutional investor has lost confidence or reallocated capital away from Travere Therapeutics. This action typically signals a negative outlook from a sophisticated market participant, prompting a 'sell' recommendation for investors to re-evaluate their positions.

Keywords

Travere Therapeutics, Macquarie Group, Schedule 13G, Beneficial Ownership, Institutional Investor, Divestment, Common Shares, SEC Filing